Table 1.10

Immunosuppression Usage by Organ in 2001 and 2002

			Organ
			Kidney	PTA	PAK	KP	Liver	Intestine	Heart	Lung	Heart-Lung
Induction Use (2002 Transplants)			65.2%	66.9%	72.5%	73.8%	17.6%	56.6%	44.8%	41.1%	59.4%
Induction Drugs (2002 Transplants)		ATG	2.0%	0.0%	2.5%	2.6%	0.5%	0.9%	7.1%	6.8%	15.6%
		OKT3	1.0%	2.5%	1.4%	0.9%	0.3%	1.9%	5.4%	0.6%	6.3%
		Thymoglobulin	25.7%	58.0%	51.2%	36.5%	4.3%	31.1%	16.3%	8.8%	3.1%
		Zenapax	13.2%	34.4%	25.9%	16.0%	4.6%	8.5%	11.1%	13.9%	15.6%
		Simulect	26.7%	4.5%	8.3%	25.2%	8.0%	14.2%	7.0%	11.5%	18.8%
Maintenance At Transplant Discharge (2002 Transplants)	Calcineurin Inhibitor Use		92.8%	98.6%	96.6%	96.0%	96.0%	95.5%	96.6%	98.1%	100.0%
		Cyclosporine	30.0%	4.1%	11.6%	9.4%	10.3%	0.0%	60.5%	42.8%	61.9%
		Tacrolimus	63.2%	95.3%	86.0%	87.1%	86.7%	95.5%	39.0%	56.7%	42.9%
	Antimetabolite Use		81.4%	65.5%	73.8%	80.0%	51.3%	11.2%	83.8%	90.3%	95.2%
		Azathioprine	2.3%	1.4%	0.3%	0.9%	3.6%	0.0%	12.4%	46.2%	52.4%
		Mycophenolate mofetil	79.3%	64.2%	73.5%	79.2%	47.7%	11.2%	75.0%	45.2%	47.6%
	Rapamycin Use		14.7%	15.5%	18.6%	17.5%	6.6%	19.1%	9.8%	1.9%	0.0%
Current Maintenance At End of First Year (2001 Transplants)	Calcineurin Inhibitor Use		92.0%	94.6%	97.0%	95.6%	94.3%	98.5%	94.0%	91.9%	100.0%
		Cyclosporine	33.7%	5.4%	11.1%	13.4%	14.6%	0.0%	53.8%	31.7%	25.0%
		Tacrolimus	58.8%	89.3%	86.4%	82.8%	82.1%	98.5%	40.8%	62.1%	75.0%
	Antimetabolite Use		75.1%	67.0%	73.2%	68.9%	30.9%	5.9%	83.1%	77.1%	85.0%
		Azathioprine	4.1%	0.9%	1.7%	1.5%	2.8%	2.9%	10.5%	31.5%	35.0%
		Mycophenolate mofetil	71.1%	66.1%	71.5%	67.4%	28.3%	2.9%	72.8%	45.5%	50.0%
	Rapamycin Use		17.3%	9.8%	22.6%	22.7%	9.8%	10.3%	6.6%	8.7%	0.0%

Source: OPTN/SRTR Data as of August 1, 2003.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may

be prescribed more than one drug within the same category.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.